Institute of environmental science and research - Riociguat an Option for Pulmonary Arterial Hypertension When PDE-5 Inhibitors Fail

Patients with pulmonary arterial hypertension at intermediate risk of death within a year may be switched from a PDE-5 inhibitor to riociguat to reduce risk, researchers...